Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort
Alessandro Conforti, Martina Gentile, Valerio Cipolloni, Laura Lucchetti et autres
Background: Real-world comparative data on treatment persistence of upadacitinib and tofacitinib in psoriatic arthritis remain limited. Because persistence reflects treatment durability, tolerability, and perceived benefit in routine practice, it may serve as a pragmatic measure of real-world effectiveness. Objective: This study aimed …
it, pl, us, ro, es, co (code pays fourni par la source)
0 citations
Frontiers in Medicine